These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine. Theobald N Drug Discov Today; 2020 Sep; 25(9):1556-1558. PubMed ID: 32592866 [No Abstract] [Full Text] [Related]
24. Contriving Multi-Epitope Subunit of Vaccine for COVID-19: Immunoinformatics Approaches. Dong R; Chu Z; Yu F; Zha Y Front Immunol; 2020; 11():1784. PubMed ID: 32849643 [TBL] [Abstract][Full Text] [Related]
25. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Lundstrom K Viruses; 2020 Nov; 12(11):. PubMed ID: 33218001 [TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2: vaccines in the pandemic era. Li DD; Li QH Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220 [TBL] [Abstract][Full Text] [Related]
27. A Thermostable mRNA Vaccine against COVID-19. Zhang NN; Li XF; Deng YQ; Zhao H; Huang YJ; Yang G; Huang WJ; Gao P; Zhou C; Zhang RR; Guo Y; Sun SH; Fan H; Zu SL; Chen Q; He Q; Cao TS; Huang XY; Qiu HY; Nie JH; Jiang Y; Yan HY; Ye Q; Zhong X; Xue XL; Zha ZY; Zhou D; Yang X; Wang YC; Ying B; Qin CF Cell; 2020 Sep; 182(5):1271-1283.e16. PubMed ID: 32795413 [TBL] [Abstract][Full Text] [Related]
28. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Sharma O; Sultan AA; Ding H; Triggle CR Front Immunol; 2020; 11():585354. PubMed ID: 33163000 [TBL] [Abstract][Full Text] [Related]
29. Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development. Huang SW; Tai CH; Hsu YM; Cheng D; Hung SJ; Chai KM; Wang YF; Wang JR Biomed J; 2020 Aug; 43(4):375-387. PubMed ID: 32611537 [TBL] [Abstract][Full Text] [Related]
30. A new generation of vaccines based on alphavirus self-amplifying RNA. Ballesteros-Briones MC; Silva-Pilipich N; Herrador-Cañete G; Vanrell L; Smerdou C Curr Opin Virol; 2020 Oct; 44():145-153. PubMed ID: 32898764 [TBL] [Abstract][Full Text] [Related]
31. A Comprehensive Review of mRNA Vaccines. Gote V; Bolla PK; Kommineni N; Butreddy A; Nukala PK; Palakurthi SS; Khan W Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36769023 [TBL] [Abstract][Full Text] [Related]
32. [At least 68 vaccine candidates under development]. Leach S Lakartidningen; 2020 Apr; 117():. PubMed ID: 32293018 [TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 Vaccines: Status Report. Amanat F; Krammer F Immunity; 2020 Apr; 52(4):583-589. PubMed ID: 32259480 [TBL] [Abstract][Full Text] [Related]
34. A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza. Andersen TK; Zhou F; Cox R; Bogen B; Grødeland G J Virol; 2017 Dec; 91(23):. PubMed ID: 28931687 [TBL] [Abstract][Full Text] [Related]
35. Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination. Tombácz I; Weissman D; Pardi N Methods Mol Biol; 2021; 2197():13-31. PubMed ID: 32827130 [TBL] [Abstract][Full Text] [Related]
36. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502 [TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Rabaan AA; Al-Ahmed SH; Sah R; Tiwari R; Yatoo MI; Patel SK; Pathak M; Malik YS; Dhama K; Singh KP; Bonilla-Aldana DK; Haque S; Martinez-Pulgarin DF; Rodriguez-Morales AJ; Leblebicioglu H Ann Clin Microbiol Antimicrob; 2020 Sep; 19(1):40. PubMed ID: 32878641 [TBL] [Abstract][Full Text] [Related]
38. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK Front Immunol; 2020; 11():1880. PubMed ID: 32973779 [TBL] [Abstract][Full Text] [Related]
39. Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2? Covián C; Retamal-Díaz A; Bueno SM; Kalergis AM Front Immunol; 2020; 11():970. PubMed ID: 32574258 [TBL] [Abstract][Full Text] [Related]
40. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Jin P; Li J; Pan H; Wu Y; Zhu F Signal Transduct Target Ther; 2021 Feb; 6(1):48. PubMed ID: 33531462 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]